By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



8 rue de la Croix Jarry

Paris    75013  France
Phone: 33-0-1-81-69-16-00 Fax: n/a




Company News
Cellectis (ALCLS) Submits IND Application For UCART123, An Allogeneic Gene Edited CAR T-Cell Product Candidate, In AML And BPDCN 1/4/2017 10:00:50 AM
Cellectis (ALCLS) Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval Of UCART123 Phase 1 Study Protocols In AML And BPDCN 12/16/2016 11:38:43 AM
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment 12/15/2016 5:19:04 PM
Cellectis (ALCLS) Reports Financial Results For 3rd Quarter And First Nine Months 2016 11/23/2016 8:05:45 AM
Cellectis (ALCLS) Announces Successful cGMP Manufacturing For Second Product Candidate: UCART123 11/16/2016 12:28:31 PM
Celyad CEO Accuses Cellectis (ALCLS)' Leader of Lying About CAR-T Patent 11/4/2016 5:46:37 AM
Cellectis (ALCLS) Announces The Issuance Of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued In December 2014 10/5/2016 10:51:29 AM
Cellectis (ALCLS) Reports 2nd Quarter And First Half Year 2016 Financial Results 9/9/2016 10:41:37 AM
MIT Technology Review Names Cellectis (ALCLS) On Annual List Of 50 Smartest Companies For Second Consecutive Year 6/28/2016 9:13:30 AM
Cellectis (ALCLS) Named 2016 Technology Pioneer By The World Economic Forum 6/28/2016 9:11:45 AM